Skip to main content

Table 4 Comparison of metabolites concentrations and enzyme activities based on fatty acid ratios between the final and the baseline status (Final vs. Baseline) in group 2 (not meeting the NAFLD criteria at baseline but meeting them during the follow-up)

From: Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

Metabolites and enzyme activities Paired Student’s t-test (p-value) log2 (fold change)
Steroids 9.05E-03 −0.38
Saturated fatty acids 1.64E-02 −0.42
Primary fatty amides 4.26E-02 −0.34
N-Acyl ethanolamines 2.39E-02 −0.23
1-Monoacylglycerophosphocholine 2.78E-02 −0.16
Monoacylglycerophosphocholine 4.00E-02 −0.14
Desaturase (MUFA + PUFA/SFA) 7.55E-04 0.39
MAPC/MAPE 8.21E-04 −0.34
LPC/LPE 5.71E-04 −0.31
(NEFA) n-6 /n-3 3.69E-02 −0.27
De novo lipogenesis (16:0/18:2n-6) 1.72E-03 −0.48
Stearoyl-CoA desaturase 1 (18:1n-9/18:0) 1.79E-02 −0.33
Elongase-6 (18:0/16:0) 3.13E-02 0.70
Delta-6- desaturase (18:3n-6/18:2n-6) 2.39E-03 −0.48
Delta-6- desaturase (18:3/18:2) 7.64E-03 −0.39
Delta-6- desaturase(18:4n-3/18:3n-3) 1.21E-02 2.72
Stearoyl-CoA desaturase 1 (16:1n-7/16:0) 1.11E-02 0.11
18:1/18:0 2.69E-02 −0.12
PUFA/MUFA 1.50E-02 0.25
  1. log2 (fold-change) and p-values follows the criterion of heatmap figure
  2. Abbreviations: SFA saturated fatty acids, PUFA polyunsaturated fatty acids, MUFA monounsaturated fatty acids, MAPC Monoacylglycerophosphocholine, MAPE Monoacylglycerophosphoethanolamine, LPC lysophosphatidylcholine, LPE lysophosphatidylethanolamine, NEFA non esterified fatty acids